Oakenhurst Medical Practice

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes3 trials
• Chronic kidney disease2 trials
• Obesity2 trials

Phase

• Phase 37 trials

Status

• Active, not recruiting3 trials
• Completed2 trials
• Not yet recruiting2 trials

Lead sponsor

• Novo Nordisk A/S3 trials
• Boehringer Ingelheim2 trials
• Eli Lilly and Company2 trials

Running trials

• Not yet recruiting

  AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

  NCT07931573· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Not yet recruiting

  A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both

  NCT07931599· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

  NCT06859268· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes2 recruiting

Closed trials

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source